Self-applied taVNS for CIPN
NCT: NCT07596030 · RECRUITING
Brief Summary
The purpose of this study is to determine the feasibility of using a portable device at home to self-administer transcutaneous auricular vagus nerve stimulation (taVNS). This handheld device has two small electrodes that are placed on specific areas of the outer ear. This device delivers a mild electrical stimulation to the vagus nerve through the ear. This study will explore how taVNS may affect symptoms of chemotherapy-induced peripheral neuropathy (CIPN). Participants will be assigned to one of two cohorts based on the presence of chemotherapy-induced peripheral neuropathy (CIPN). Participants with CIPN will be placed in the intervention cohort (n=24) and will complete a 2-week trial of daily self-applied taVNS. Participants without CIPN will be placed in the registry cohort (n=12) and will complete study measurements without receiving the intervention. The registry cohort will not receive the taVNS intervention but will undergo identical physiological assessments at baseline and at a 2 week follow up to control for testing effects and biological variability.
Frequently Asked Questions
What is Self-applied taVNS for CIPN?
Self-applied taVNS for CIPN is a clinical trial registered under NCT07596030. Current status: RECRUITING.
What is the status of NCT07596030?
The current status of NCT07596030 (Self-applied taVNS for CIPN) is: RECRUITING.
When did Self-applied taVNS for CIPN start?
Self-applied taVNS for CIPN started on 2026-06-02.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.